Literature DB >> 29920474

The short chain fatty acids and lipopolysaccharides status in Sprague-Dawley rats fed with high-fat and high-cholesterol diet.

D Maciejewska1, K Skonieczna-Zydecka2, A Lukomska2, I Gutowska2, K Dec2, P Kupnicka3, J Palma2, A Pilutin4, W Marlicz5, E Stachowska2.   

Abstract

Short chain fatty acids (SCFA) are produced by the gut microbiota during the fermentation of non-digestible polysaccharides. Diet is a major factor driving the composition and metabolism of the colonic microbiota. The aim of our study was to examine how a fat-rich and cholesterol-rich diet that, which leads to many metabolic disorders, affects the SCFA profile and lipopolysaccharide (LPS) concentration. The experiment was carried out on 72 male, 8-weeks-old Sprague-Dawley rats. The study group (n = 30 rats) received high-fat and high cholesterol diet (HFHCh). The control group (n = 30) received standard food for laboratory rats. The rats from study and control groups were sacrificed after 4, 8, 12, 16 and 20 weeks after start of dietary exposure. The analysis of SFA in feces was performed using gas chromatography (Agilent Technologies 1260 A GC). The exposure to high-fat and high-cholesterol diet was associated with significant changes in SCFA levels. Relative to the control, each of HFHCh subgroup revealed a statistically significant decrease in butyrate (12.5% ± 5.7% versus 32.8% ± 9.1%) and an increase in propionate level (45.4% ± 6.2% versus 19.14% ± 7.1%). The ratio of acetate: propionate: butyrate was also changed (from 1.1: 0.6: 1 for control groups to 3 : 3,6 : 1 for HFHCh groups). The main SCFA in the HFHCh group was propionate instead of acetate. The dietary exposure resulted in significant differences in LPS concentration. After 12 weeks of HFD exposure, LPS concentration was significantly higher compared to control groups (P < 0.05). Our study showed that HFHCh diet affected butyrate and propionate production associated with an increase in LPS secretion. The hypothesis that observed changes could result in intestinal imbalance secondary to gut barrier dysfunction requires further studies.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29920474     DOI: 10.26402/jpp.2018.2.05

Source DB:  PubMed          Journal:  J Physiol Pharmacol        ISSN: 0867-5910            Impact factor:   3.011


  6 in total

1.  Renal Sensing of Bacterial Metabolites in the Gut-kidney Axis.

Authors:  Orestes Foresto-Neto; Bruno Ghirotto; Niels Olsen Saraiva Câmara
Journal:  Kidney360       Date:  2021-07-02

Review 2.  The Role of Gut Microbiota in Intestinal Inflammation with Respect to Diet and Extrinsic Stressors.

Authors:  Stefani Lobionda; Panida Sittipo; Hyog Young Kwon; Yun Kyung Lee
Journal:  Microorganisms       Date:  2019-08-19

3.  The fungal community and its interaction with the concentration of short-chain fatty acids in the faeces of Chenghua, Yorkshire and Tibetan pigs.

Authors:  Jiayan Li; Daiwen Chen; Bing Yu; Jun He; Zhiqing Huang; Xiangbing Mao; Ping Zheng; Jie Yu; Junqiu Luo; Gang Tian; Yuheng Luo
Journal:  Microb Biotechnol       Date:  2019-11-05       Impact factor: 5.813

Review 4.  Role of Obesity, Mesenteric Adipose Tissue, and Adipokines in Inflammatory Bowel Diseases.

Authors:  Jan Bilski; Agnieszka Mazur-Bialy; Dagmara Wojcik; Marcin Surmiak; Marcin Magierowski; Zbigniew Sliwowski; Robert Pajdo; Slawomir Kwiecien; Aleksandra Danielak; Agata Ptak-Belowska; Thomas Brzozowski
Journal:  Biomolecules       Date:  2019-11-26

5.  The Associations of SCFA with Anthropometric Parameters and Carbohydrate Metabolism in Pregnant Women.

Authors:  Małgorzata Szczuko; Justyna Kikut; Dominika Maciejewska; Danuta Kulpa; Zbigniew Celewicz; Maciej Ziętek
Journal:  Int J Mol Sci       Date:  2020-12-03       Impact factor: 5.923

Review 6.  Intestinal Inflammation and Alterations in the Gut Microbiota in Cystic Fibrosis: A Review of the Current Evidence, Pathophysiology and Future Directions.

Authors:  Rachel Y Tam; Josie M van Dorst; Isabelle McKay; Michael Coffey; Chee Y Ooi
Journal:  J Clin Med       Date:  2022-01-27       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.